D. J. Argyle

2.1k total citations
61 papers, 1.4k citations indexed

About

D. J. Argyle is a scholar working on Molecular Biology, Genetics and Oncology. According to data from OpenAlex, D. J. Argyle has authored 61 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 21 papers in Genetics and 18 papers in Oncology. Recurrent topics in D. J. Argyle's work include Virus-based gene therapy research (15 papers), Veterinary Oncology Research (14 papers) and Cancer Cells and Metastasis (8 papers). D. J. Argyle is often cited by papers focused on Virus-based gene therapy research (15 papers), Veterinary Oncology Research (14 papers) and Cancer Cells and Metastasis (8 papers). D. J. Argyle collaborates with scholars based in United Kingdom, United States and Netherlands. D. J. Argyle's co-authors include Lisa Y. Pang, Karine Savary-Bataille, L. Nasir, E. A. Gault, Felisbina L. Queiroga, Teresa P. Raposo, Sue Murphy, Heather Wilson‐Robles, Laura Blackwood and Mark Gray and has published in prestigious journals such as Oncogene, Scientific Reports and Gene.

In The Last Decade

D. J. Argyle

60 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. J. Argyle United Kingdom 22 608 415 339 336 285 61 1.4k
Jeffrey N. Bryan United States 21 668 1.1× 369 0.9× 264 0.8× 308 0.9× 285 1.0× 89 1.5k
Robert B. Rebhun United States 27 877 1.4× 492 1.2× 403 1.2× 393 1.2× 504 1.8× 95 1.9k
Jessica Lawrence United States 20 605 1.0× 317 0.8× 157 0.5× 165 0.5× 154 0.5× 77 1.2k
Frédérique Nguyen France 17 466 0.8× 319 0.8× 248 0.7× 206 0.6× 116 0.4× 39 1.0k
Michael D. Lucroy United States 19 742 1.2× 115 0.3× 125 0.4× 240 0.7× 221 0.8× 61 1.3k
Munekazu NAKAICHI Japan 18 363 0.6× 181 0.4× 173 0.5× 168 0.5× 186 0.7× 101 1.0k
Wallace B. Morrison United States 19 712 1.2× 148 0.4× 166 0.5× 233 0.7× 303 1.1× 44 1.1k
Christina Mertens Germany 23 304 0.5× 863 2.1× 280 0.8× 105 0.3× 60 0.2× 41 2.1k
François Plénat France 27 333 0.5× 665 1.6× 347 1.0× 34 0.1× 156 0.5× 95 2.0k
Sue E. Knoblaugh United States 23 154 0.3× 1.1k 2.7× 706 2.1× 54 0.2× 173 0.6× 47 2.5k

Countries citing papers authored by D. J. Argyle

Since Specialization
Citations

This map shows the geographic impact of D. J. Argyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. J. Argyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. J. Argyle more than expected).

Fields of papers citing papers by D. J. Argyle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. J. Argyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. J. Argyle. The network helps show where D. J. Argyle may publish in the future.

Co-authorship network of co-authors of D. J. Argyle

This figure shows the co-authorship network connecting the top 25 collaborators of D. J. Argyle. A scholar is included among the top collaborators of D. J. Argyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. J. Argyle. D. J. Argyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Buishand, Floryne O., et al.. (2017). Notch pathway inhibition targets chemoresistant insulinoma cancer stem cells. Endocrine Related Cancer. 25(2). 131–144. 31 indexed citations
2.
Vos, Johannes de, Martin Kessler, Pauline De Fornel, et al.. (2017). Combination toceranib and lomustine shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study. The Veterinary Journal. 224. 1–6. 9 indexed citations
3.
Gray, Mark, et al.. (2016). Dual targeting of EGFR and ERBB2 pathways produces a synergistic effect on cancer cell proliferation and migration in vitro. Veterinary and Comparative Oncology. 15(3). 890–909. 11 indexed citations
4.
Flanagan, Thomas C., et al.. (2015). Culture and characterisation of canine mitral valve interstitial and endothelial cells. The Veterinary Journal. 204(1). 32–39. 17 indexed citations
5.
Pang, Lisa Y., R. W. Else, Adrian Sherman, et al.. (2012). Feline mammary carcinoma stem cells are tumorigenic, radioresistant, chemoresistant and defective in activation of the ATM/p53 DNA damage pathway. The Veterinary Journal. 196(3). 414–423. 17 indexed citations
6.
Waterfall, Martin, et al.. (2011). CD44 is associated with proliferation, rather than a specific cancer stem cell population, in cultured canine cancer cells. Veterinary Immunology and Immunopathology. 141(1-2). 46–57. 27 indexed citations
7.
Waterfall, Martin, et al.. (2011). Flow cytometric techniques for detection of candidate cancer stem cell subpopulations in canine tumour models. Veterinary and Comparative Oncology. 10(4). 252–273. 14 indexed citations
8.
Savary-Bataille, Karine, et al.. (2010). Development of a questionnaire assessing health‐related quality‐of‐life in dogs and cats with cancer. Veterinary and Comparative Oncology. 9(3). 172–182. 95 indexed citations
9.
Turek, Michelle, et al.. (2007). Evaluation of the gene for inducible nitric oxide synthase as a radiosensitizer under hypoxic and oxic conditions. Veterinary and Comparative Oncology. 5(4). 250–255. 5 indexed citations
10.
11.
12.
McMonagle, Elizabeth L., et al.. (2004). Bioactivity and secretion of interleukin-18 (IL-18) generated by equine and feline IL-18 expression constructs. Veterinary Immunology and Immunopathology. 102(4). 421–428. 8 indexed citations
13.
Cave, T. A., E. A. Gault, & D. J. Argyle. (2004). Feline epitheliotrophic T‐cell lymphoma with paraneoplastic eosinophilia – immunochemotherapy with vinblastine and human recombinant interferon α2b. Veterinary and Comparative Oncology. 2(2). 91–97. 12 indexed citations
14.
Cave, T. A., Victoria Johnson, Thierry Beths, Richard Edwards, & D. J. Argyle. (2003). Treatment of unresectable hepatocellular adenoma in dogs with transarterial iodized oil and chemotherapy with and without an embolic agent: A report of two cases. Veterinary and Comparative Oncology. 1(4). 191–199. 17 indexed citations
15.
Nasir, L., et al.. (2001). Analysis of p53 mutational events and MDM2 amplification in canine soft-tissue sarcomas. Cancer Letters. 174(1). 83–89. 35 indexed citations
16.
Taylor, Simon, Linda Hanlon, E. A. Gault, et al.. (2000). Cloning and Sequencing of Feline and Canine Ice-Related cDNAs Encoding Hybrid Caspase-1 / Caspase-13-Like Propeptides. DNA sequence. 10(6). 387–394. 5 indexed citations
17.
Argyle, D. J., et al.. (1999). Nucleotide Sequence of Equine Caspase-1 cDNA. DNA sequence. 10(2). 133–137. 2 indexed citations
18.
19.
Nasir, L., D. J. Argyle, Steven McFarlane, & S. W. J. Reid. (1997). Nucleotide Sequence of a Highly Conserved Region of the Canine p53 Tumour Suppressor Gene. DNA sequence. 8(1-2). 83–86. 14 indexed citations
20.
Argyle, D. J., et al.. (1995). Nucleotide and predicted peptide sequence of feline interferon—gamma (IFN-γ). DNA sequence. 5(3). 169–171. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey N. Bryan Breakdown of academic impact, for papers by Robert B. Rebhun Breakdown of academic impact, for papers by Jessica Lawrence Breakdown of academic impact, for papers by Frédérique Nguyen Breakdown of academic impact, for papers by Michael D. Lucroy Breakdown of academic impact, for papers by Munekazu NAKAICHI Breakdown of academic impact, for papers by Wallace B. Morrison Breakdown of academic impact, for papers by Christina Mertens Breakdown of academic impact, for papers by François Plénat Breakdown of academic impact, for papers by Sue E. Knoblaugh
Rankless by CCL
2026